ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 755,00
0,41%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Denali Therapeutics Inc (DNLI)

  7. Denali Therapeutics Inc (DNLI) Actualités

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DNLI
DateHeureSourceTitreSymboleSociété
31/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
07/05/202422h01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
01/03/202422h51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
16/02/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
14/02/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
07/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
01/02/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
08/01/202414h00GlobeNewswire Inc.Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNASDAQ:DNLIDenali Therapeutics Inc
28/11/202301h01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:DNLIDenali Therapeutics Inc
21/11/202312h00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:DNLIDenali Therapeutics Inc
07/11/202322h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DNLIDenali Therapeutics Inc
07/11/202322h01GlobeNewswire Inc.Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/11/202315h30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:DNLIDenali Therapeutics Inc
11/09/202312h30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:DNLIDenali Therapeutics Inc
30/08/202314h30GlobeNewswire Inc.Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023NASDAQ:DNLIDenali Therapeutics Inc
29/08/202315h00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:DNLIDenali Therapeutics Inc
08/08/202322h01GlobeNewswire Inc.Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
21/06/202312h00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DNLIDenali Therapeutics Inc
21/06/202312h00PR Newswire (US)Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule DrugsNASDAQ:DNLIDenali Therapeutics Inc
20/06/202313h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DNLIDenali Therapeutics Inc
20/06/202313h00GlobeNewswire Inc.Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)NASDAQ:DNLIDenali Therapeutics Inc
16/06/202323h37Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:DNLIDenali Therapeutics Inc
16/05/202312h00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:DNLIDenali Therapeutics Inc
08/05/202322h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DNLIDenali Therapeutics Inc
08/05/202322h01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
18/04/202322h08Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DNLIDenali Therapeutics Inc
18/04/202322h05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

Dernières Valeurs Consultées

LSE
61VU
Sg Issuer 23
HUOB
BSVBTC
TG
SPPR
SPDR Bloomberg SASB Euro...
COIN
BBLETH
BUBBLE
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés